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Abstract
Background: Liqi, an herbal preparation used in traditional Chinese medicine, has been used to
treat cancer in China for centuries. We investigated the anti-tumor effects of liqi and their
mechanisms in mice that had been xenografted with tumors.
Methods: Sarcoma 180 tumor, Lewis lung carcinoma, and SGC-7901 cells were implanted in
BALB/c mice, C57BL/6 mice, and BALB/c nude mice, respectively. Liqi was administered to
subgroups of these mice. The tumor weight and size were measured. Cell cycle analysis and T
lymphocyte subsets were determined by flow cytometry. The activity of NK cells and TNF was
tested using cytotoxicity assay on YAC-1 cells and L929 cells, respectively, and the activity of IL-2
was tested with an IL-2-dependent CTLL-2 cell proliferation assay. Platelet aggregation was
monitored by measuring electric impedance, and the levels of thromboxane A2 (TXA2) and
prostacyclin (PGI2) in blood were measured by 125I-TXB2 and 125I-Keto-PGF1α radioimmunoassay.
Results:  The results showed that liqi inhibited tumor growth in tumor-implanted mice and
arrested the cell proliferation in the G0/G1 phase and reduced the portion of cells in S and G2/M
phase for SGC-7901 cells. Liqi increased the activity of NK cells and TNF-α, stimulated IL-2
production and activity, and regulated T lymphocyte subpopulations. Liqi inhibited the Lewis lung
carcinoma metastasis by inhibiting platelet aggregation and normalizing the balance between TXA2
and PGI2.
Conclusion:  All these findings demonstrated that liqi has an anti-tumor effect in vivo. The
mechanism may be related to immune regulation and anticoagulation effects.
Background
Cancer is a leading cause of death worldwide. The main
curative therapies for cancer are surgery and radiation,
although these are most successful if the tumor is diag-
nosed at an early stage. For advanced tumors, chemother-
apy is the treatment of choice, and although these drugs
are effective, they are associated with severe adverse events
and drug resistance [1], and new therapeutic options are
needed. In the search for new cancer therapeutics with low
toxicity and few side effects, traditional Chinese medi-
cines are promising candidates.
Published: 1 July 2009
BMC Complementary and Alternative Medicine 2009, 9:20 doi:10.1186/1472-6882-9-20
Received: 19 August 2008
Accepted: 1 July 2009
This article is available from: http://www.biomedcentral.com/1472-6882/9/20
© 2009 Ji et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Complementary and Alternative Medicine 2009, 9:20 http://www.biomedcentral.com/1472-6882/9/20
Page 2 of 9
(page number not for citation purposes)
Liqi  prescription, a traditional Chinese medicine made
from Poncirus trifoliate (L.)Raf, Akebia Trifoliate Koidz, Cit-
rus medica var. sarcodactylis Swingle and Saussurea lappa, has
been used to treat malignancies in traditional Chinese
medicine for centuries. The main active constituents are
coumarins, flavonoids, and terpenoids in Poncirus trifoli-
ate (L.)Raf; triterpene and triterpenoid saponin in Akebia
Trifoliate Koidz; terpene, flavonoids and polysaccharide in
Citrus medica var. sarcodactylis Swingle; and sesquiterpenes
and sesquiterpene lactones in Saussurea lappa[2-5]. Recent
studies have demonstrated their multiple pharmacologic
actions, including anti-inflammatory, anti-allergic and
antibacterial effects; promoting gastrointestinal motor
function; and inhibiting cancer cell growth in vitro. Ponci-
rus trifoliate inhibits human colon cancer HT-29 cell
growth and induces human leukemia HL-60 cell apopto-
sis [6,7]. Akebia Trifoliate Koidz inhibits the growth of
breast cancer cell lines MDA-MB-231 and BT-483[8]. Saus-
surea lappa induces G2-growth arrest and apoptosis in AGS
gastric cancer cells [9].
However, little research has been conducted on the anti-
tumor effects of liqi in vivo. In the present experiment, we
studied the anti-tumor effect of liqi and explored the
mechanism of any effect on tumor-bearing mice.
Methods
Materials
Poncirus trifoliate (L.)Raf, Akebia Trifoliate Koidz, Citrus
medica var. sarcodactylis Swingle and Saussurea lappa were
purchased from Shanghai Pharmaceutical Co., Shanghai,
China, and were authenticated by Prof. Bo-Wen Qian,
Department of Traditional Chinese Medicine, Shanghai
University of Chinese Traditional Medicine, Shanghai,
China. We also used the following materials: Concanava-
lin A (ConA), lipopolysaccharide (LPS), propidium
iodide, ADP (Sigma, St Louis, MO); [3H]TdR (China Insti-
tute of Atomic Energy, Beijing, China); human recom-
binant interleukin-2 (rhIL-2) (Boehringer Mannhein
GmbH, Germany); human recombinant tumor necrosis
factor (TNF) (Collaborative Biomedical Products, Bed-
ford, MA); FITC-conjugated antibodies to CD3, CD4,
CD8 (Pharmingen, Becton Dickinson, Franklin Lakes,
NJ); lactic dehydrogenase (LDH) Cytotox assay kit
(Promega, Madison, WI); 125I-TXB2 and  125I-Keto-PGF1α
radioimmunoassays (RIA kits, Suzhou Medical College,
Suzhou, China); RPMI Medium 1640 (Invitrogen, Carlsa-
bad, CA); fetal bovine serum (FBS, HyClone Corporation,
Logan, UT).
Cell culture
Mouse sarcoma 180 tumor cells, Lewis lung carcinoma
cells, and human gastric carcinoma cell line SGC-7901
were donated by Shanghai Institute of Materia Medica,
Chinese Academy of Sciences (Shanghai, China). YAC-1,
CTLL-2, and L929 cells were provided by School of Medi-
cine, Shanghai Jiao Tong University (Shanghai, China),
and were grown routinely in RPMI-1640 supplemented
with 10% heat-inactivated fetal bovine serum (FBS). The
medium was supplemented with 100 U/mL penicillin and
100 U/mL streptomycin; 10 ng/mL rhIL-2 was added in
the culture medium of CTLL-2 cells, and the cells were
incubated in a humidified atmosphere, with 5% CO2 in
air at 37°C.
Animals
Male BALB/c mice and C57BL/6 mice (6 to 8 weeks old)
were provided by the Department of Shanghai Institute of
Planned Parenthood Research, Fudan University, Shang-
hai, China. The animals were group-housed in a regulated
environment (22 ± 1°C, relative humidity 60 ± 5%) with
a 12-h light and 12-h dark cycle (08:00–20:00, light).
Food and water were given ad libitum. Food pellets meet
Feed Standard of Medical Laboratory Animal of China.
Food composition is as follows: protein18–25%, fat 4–
5%, calcium 1.0–1.8%, phosphonium0.6–1.2%, vitamins
A 12500–15000 IU/kg, vitamins D 1250–1500 IU/kg,
fiber 4–5% and moisture 8–10%, lysine 0.98–1.42%,
cystine0.76–1.10%, tryptophane 0.22–0.34%.
BALB/c strain athymic nu/nu mice were provided by
Shanghai Cancer Institute, China. Female mice (6 to 8
weeks old) were used in this study. The animals were
maintained in a specific pathogen free animal care facility,
under controlled conditions (25 ± 2°C, 50%–60% rela-
tive humidity and 12-hour light cycle). They were fed with
autoclaved tap water and food ad libitum. The laboratory
animal protocol used for this study was approved by the
committee for control and supervision of experimental
animals of Shanghai University of Chinese Traditional
Medicine.
Preparation of Liqi
Liqi was prepared as a lyophilized powder of hot water
extracts from 4 species of medical herbs: Citrus medica var.
sarcodactylis Swingle, Akebia Trifoliate Koidz, Poncirus trifoli-
ata(L.)Raf and Saussurea lappa. Briefly, the above materials
were mixed in a ratio of 3:2:1.7:1.7 and decocted three
times with boiling distilled water for 1 h. The decoction
was filtered, collected, concentrated, and lyophilized. The
yield of liqi was approximately 20%. Liqi was dissolved in
distilled water and administered in a volume of 10 ml/kg.
In this experiment, the animal dose of liqi was dose of
crude drug.
Tumor models and in vivo treatment regimen
Sarcoma 180 tumor cells were subcutaneously implanted
(2 × 106 S180 tumor cells suspended in 50 μl of Ca2+- and
Mg2+-free phosphate-buffered saline [PBS]) in the right
axillary region of syngeneic BALB/c mice. Lewis lung car-
cinoma cells were subcutaneously implanted (2 × 106 LLC
tumor cells suspended in 50 μl of PBS) in the right axillaryBMC Complementary and Alternative Medicine 2009, 9:20 http://www.biomedcentral.com/1472-6882/9/20
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region of syngeneic C57BL/6 mice. SGC-7901 cells were
subcutaneously implanted (2×105 cells suspended in 0.2
ml of PBS) in the right axillary region of BALB/c nude
mice. After 24 h, they were weighed and randomized into
5 groups (12 mice each): a normal control group, a group
that was injected with tumor cells but treated with water
only, and three groups that were injected with tumor cells
and treated with different doses of liqi (12.5, 25 and 50 g/
kg). Treatments were administrated at about 9 o'clock
daily by gavage, and mice were weighted daily.
Anti-tumor activity
On day 21, all mice were weighed and euthanized, and
tumors were removed and weighed. The tumor repression
rate was calculated as follows: The repression rate (%) =
(mean weight of tumors of water-treated mice – mean
weight of tumors of liqi-treated mice)/mean weight of
tumors of water-treated mice × 100% [10].
Cell cycle analysis of SGC-7901 cells from xenografted 
mice
For cell cycle analysis, cells were harvested from
xenografted BALB/c nude mice. On day 21, tumor tissues
were immediately removed and disaggregated in PBS and
filtered through a double layer of stainless-steel mesh
using a syringe plunger to obtain single cell suspension.
Cell cycle distribution was evaluated by propidium iodide
staining of nuclei and flow cytometric analysis [11].
Briefly, pelleted cells were washed twice with PBS and
then fixed in 70% cold ethanol overnight at -20°C. After
washing again, the cells were resuspended in PBS contain-
ing RNase A (200 μg/mL) and incubated at 37°C for 30
min. Propidium iodide was added to the cell suspensions
at a final concentration of 100 μg/mL. The fluorescence
intensity of PI was analyzed with a FACS calibur flow
cytometer (FACS Calibur; Becton Dickinson, USA) and
Cell Quest software.
Flow cytometry for peripheral blood T lymphocyte subsets
On day 12, the heparinized peripheral blood was col-
lected from the orbital plexuses of the tumor-bearing
C57BL/6 mice to analyze peripheral blood lymphocyte
subsets by flow cytometry. Samples were prepared by add-
ing 5 μl of fluorescent monoclonal antibodies against
CD3, CD4, and CD8 to 100 μl of heparinized whole
blood. CD3+CD4+ (T helper cells) and CD3+CD8+ (T
suppressor cells) were counted. Lymphocytes were sepa-
rated from erythrocytes lysed. The tubes were placed on
ice in the dark until flow cytometric analysis; five thou-
sand cells were collected for each sample, and data were
analyzed by using flow cytometry.
IL-2 activity assay
In order to determine the effects of Liqi on IL-2 produc-
tion and activity, splenic lymphocytes from tumor bearing
BALB/c mice were prepared after treatment with liqi (50 g/
kg) for 12 days as described above. Spleens of mice were
removed under sterile conditions and disaggregated in
PBS and filtered through a double layer of stainless-steel
mesh using a syringe plunger to obtain single-cell suspen-
sion. Lymphocytes were collected and suspended in
RPMI-1640 medium at a concentration of 1×107 cells/mL,
with ConA added to a final concentration of 5 μg/mL.
After incubating at 37°C and 5% CO2 for 24 hours, cells
supernatants containing extracellular IL-2 were collected
and stored at -20°C until assay.
IL-2 activity was tested using an IL-2-dependent CTLL-2
cell proliferation assay [12]. The CTLL-2 cells were washed
in medium containing 2% FBS and incubated for 2 h
without IL-2. The cells were then cultured (1× 105 cells/
mL) in 96-well plates with 0.6 ng/mL of rhIL-2 or with
spleen cell supernatant for 24 h. Six hours before the end,
0.5  μCi [3H]TdR 50 μL was added to each well. The
[3H]TdR incorporation was measured with a liquid-scin-
tillator (Beckman Co, USA) counting technique. The
results were described as the average of triplicate Bq (spe-
cific radioactivity of [3H]TdR was 20 μCi/mmol).
Evaluation of NK cell cytotoxicity
NK cells from tumor bearing BALB/c mice spleens were
prepared as described above and used as effector cells.
YAC-1 cells, mouse lymphoma sensitive to NK cells were
used as target cells. Effector and target cells resuspended in
RPMI-1640 medium were added to each well of a 96-well
round-bottom microculture plate in triplicate to obtain an
effector/target (E/T) ratio of 100:1 and incubated for 16 h.
The amount of released lactate dehydrogenase (LDH) in
culture supernatants was determined using the LDH Cyto-
tox assay kit according to the manufacturer's instructions.
The OD was read at 490 nm with a Microplate Reader. The
percentage of NK cell cytotoxicity was calculated with the
formula: cytotoxicity (%) = (experimental release – effec-
tor spontaneous release – target spontaneous release)/
(target maximum release – target spontaneous release) ×
100. Experimental release stood for LDH that was released
from cocultures at an E/T ratio of 100:1, effector sponta-
neous release or target spontaneous release was spontane-
ous LDH release from effector or target cells incubated
with medium alone, and target maximum release was
obtained from target cells lysed with the lysis solution
[13].
Production and activity assay of TNF
On day 12, tumor-bearing BALB/c mice received 20 μg/
0.2 ml of LPS intravenously. After 1.5 h, blood samples
were collected from the orbital plexuses of the mice. The
sera were stored at -20°C until used for the TNF assay.
TNF activity was determined by a cytotoxicity assay on
L929 cells [14]. Briefly, L929 cells were plated at the den-
sity of 3.5 × 104/ml in 96-well plates and incubated at
37°C in a 5% CO2 atmosphere for 24 h. Samples orBMC Complementary and Alternative Medicine 2009, 9:20 http://www.biomedcentral.com/1472-6882/9/20
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recombinant TNF (as the standard) were incubated for a
further 24 h, in the presence of 2 μg/ml actinomycin D.
Cell survival was determined by measuring optical density
at 630 nm after crystal violet staining. The diluted samples
were assayed in triplicate. The percentage of cell destruc-
tion at a particular dilution was calculated as (Acont – Adil/
Acont) × 100, where Acont is absorbance in control wells
and Adil is absorbance in wells of a particular dilution of
sample. The percent cytotoxicities were plotted against the
logarithm of sample quantity. One unit of TNF activity
was defined as the sample quantity required to achieve
50% cytotoxicity in the reaction.
Inhibition of Metastasis in Mice
The tumor-bearing C57BL/6 mice were sacrificed on the
21st day. Lungs were removed and fixed in 4% formalin.
Tumor colonies were counted under microscope (× 200).
Platelet Aggregation Assay
Platelet aggregation was monitored by measuring electric
impedance [15] using a whole-blood aggregometer
(model OX-200; Shanghai Medical University Instrument
Factory, Shanghai, China). On day 21, heparinized blood
was drawn from tumor-bearing C57BL mice by cardiac
puncture. Whole blood was then diluted with an equal
amount of normal saline. The sample was placed in a
plastic cuvette containing a magnetic stir bar and was kept
at 37°C for 5 minutes before analysis. The platelet aggre-
gation was then initiated by adding 10 μl 2 μmol/L ADP
and monitored for up to 5 minutes.
Measurement of TXA2 and PGI2
On day 21, blood samples were collected from the femo-
ral artery of the tumor-bearing C57BL/6 mice and trans-
ferred into a plastic tube prefilled with EDTA-Na2 (9:1).
The tube was centrifuged at 1200 × g at 4°C for 10 min.
The supernatant was frozen at -20°C. TXA2 with a half-life
of approximately 30 sec under physiologic conditions was
measured using its stable metabolite TXB2, and PGI2 using
its stable metabolite 6-keto-prostaglandin F1α [16]. All
determinations were performed using commercially avail-
able  125I-TXB2 and  125I-Keto-PGF1α radioimmunoassays
(RIA kits, Suzhou Medical College, Suzhou, China).
Statistical analysis
The data are expressed as mean ± S.D. Student's t-test or
Dunnet  t-test was used to compare the differences
between treated groups and control groups, and differ-
ences were considered significant at P < 0.05.
Results
Effect of liqi on tumor growth in the tumor-transplanted 
mice
To explore the role of liqi on tumor growth in mouse Sar-
coma 180 transplanted into BALB/c mice and Lewis lung
carcinoma transplanted into C57BL/6 mice, we treated
tumor-bearing mice with various doses of liqi (12.5, 25,
50 g/kg). For Sarcoma 180-bearing BALB/c mice, liqi sig-
nificantly decreased the tumor growth, with 29.69% inhi-
bition at 25 g/kg and 34.54% inhibition at 50 g/kg (p <
0.05, Table 1). For Lewis lung carcinoma-bearing C57BL/
6 mice, liqi significantly decreased the tumor growth, with
35.20% inhibition at 25 g/kg and 42.54% inhibition at 50
g/kg (p < 0.05, Table 2). There was no significant differ-
ence between the body weight of the liqi-treated group
and that of the normal group.
To determine whether liqi could suppress human gastric
carcinoma growth in vivo, we implanted SGC-7901 in
nude mice. As shown in Figure 1, Liqi (50 g/kg) reduced
the tumor weight significantly compared with the model
group (p < 0.05), with inhibition 27.42%.
Effect of Liqi on SGC-7901 cells cycle from xenografted 
mice
As shown in Table 3, cell cycle analysis showed accumula-
tion of SGC-7901 cells in the G0/G1 phase (p < 0.01) and
decreased cell numbers in the S (p<0.01) and G2/M
phases in mice treated with 50 g/kg of liqi.
Effect of liqi on T lymphocyte subpopulations in tumor-
bearing mice
As shown in Figure 2, the numbers of CD3+ CD4+ T cells
and the CD4+/CD8+ ratios in peripheral blood were con-
sistently lower in the tumor-bearing mice than in the nor-
mal mice (P < 0.05). Among tumor-bearing mice, those
treated with liqi had consistently higher percentages of
Table 1: Effect of Liqi on mouse Sarcoma 180 transplanted into BALB/c mice
Groups Doses (g/kg) n Mean weight of tumor (g) Inhibition (%)
Normal 0 12 0 0
Model 0 12 1.65 ± 0.47 0
Liqi 12.5 12 1.28 ± 0.50 22.42%
25 12 1.16 ± 0.49* 29.69%
50 12 1.08 ± 0.50* 34.54%
Each group consists of 12 mice. Results are presented as mean ± S.D. *P < 0.05, compared with model group.BMC Complementary and Alternative Medicine 2009, 9:20 http://www.biomedcentral.com/1472-6882/9/20
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CD3+CD4+ T lymphocytes than did untreated mice (P <
0.05). A similar difference was seen in the ratios of CD4+/
CD8+; however, the percentages of CD3+CD8+ T lym-
phocytes were slightly lower in liqi-treated mice.
Effect of liqi on IL-2 activity in tumor-bearing mice
To illustrate whether liqi could affect the IL-2 production
and activity in splenocytes, the murine T-cell line CTLL-2
was used. As shown in Figure 3, splenocytes supernatants
from tumor-bearing mice inhibited the proliferation of
CCLL-2 cells compared with the normal group (P < 0.01).
After treatment with liqi (50 g/kg), splenocyte superna-
tants showed a greater proliferation of CCLL-2 cells than
in splenocytes from untreated mice (P < 0.01).
Effect of liqi on NK cell cytotoxicity in tumor-bearing mice
The activation of NK cells is a good indicator of antitumor
effect. After tumor-bearing mice were treated with liqi (50
g/kg), splenic lymphocytes showed more cytotoxicity
than did splenocytes from untreated mice (P < 0.05) (Fig-
ure 4). These results indicate that liqi increased NK cell
cytotoxicity.
Effect of liqi on TNF-α activity in tumor-bearing mice
We checked whether Liqi interfered in the LPS-induced
TNF-α activity in tumor bearing mice. As shown in Figure
5, Liqi (50 g/kg) significantly increased TNF-α cytotoxicity
on L929 cells (P < 0.01).
Effect of liqi on metastasis of tumor cells to the lung
As shown in Figure 6, liqi prevented metastases to the
lung. Fewer tumor colonies were observed in the lungs of
mice treated with liqi compared with untreated mice (P <
0.05). The inhibition effect was 33.89%.
Effect of liqi on platelet aggregation in tumor-bearing mice
As shown in Figure 7, increased platelet aggregation was
observed in tumor-bearing mice compared with the nor-
mal group (P < 0.05); however, liqi (50 g/kg) significantly
decreased platelet aggregation compared with untreated
mice (P < 0.05).
Effect of liqi on TXA2 and PGI2 in tumor-bearing mice
As shown in Table 4, TXB2 concentration was increased
and 6-Keto-PGF1α was decreased in the blood plasma of
tumor-bearing mice compared with normal group (P <
0.01); consequently, the ratio of TXB2 to 6-Keto-PGF1α
was significantly increased compared with that of the nor-
mal group (P < 0.01). However, when the tumor-bearing
mice were treated with liqi (50 g/kg), the level of TXB2 was
markedly lowered, 6-Keto-PGF1α was raised, and the ratio
Table 2: Effect of Liqi on mouse Lewis lung carcinoma transplanted into C57BL/6 mice.
Groups Doses (g/kg) n Mean weight of tumor (g) Inhibition (%)
Normal 0 12 0 0
Model 0 12 1.57 ± 0.62 0
Liqi 12.5 12 1.11 ± 0.51 29.06%
25 12 1.02 ± 0.48* 35.20%
50 12 0.90 ± 0.44* 42.54%
Each group consists of 12 mice. Results are presented as mean ± S.D. *P < 0.05, compared with model group.
Effect of Liqi on SGC7901 transplanted into BALB/c nu/nu  mice Figure 1
Effect of Liqi on SGC7901 transplanted into BALB/c 
nu/nu mice. SGC-7901 cells were subcutaneously 
implanted (2 × 105 cells suspended in 0.2 ml of PBS) in the 
right axillary region of BALB/c nude mice. After 24 h, Liqi 
(12.5, 25, 50 g/kg) was administrated daily by gavage for 21 
days. The tumor weight was measured. Results are 
expressed as the mean ± S.D. of 12 mice. *P < 0.05, com-
pared with untreated control of tumor-transplanted animals 
(model group).
Table 3: Effect of Liqi on cell cycle of SGC-7901 cells from 
xenografted mice.
Groups Dose(g/kg) n Cell cycle (%)
G1 S G2+M
Model 0 7 49.7 ± 6.8 44.9 ± 6.6 5.4 ± 0.76
Liqi 50 7 61.8 ± 6.4** 34.0 ± 5.3** 4.13 ± 1.2
Each group consists of 7 mice. Results are presented as mean ± S.D. 
**P < 0.01, compared with model group.BMC Complementary and Alternative Medicine 2009, 9:20 http://www.biomedcentral.com/1472-6882/9/20
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of TXB2 to 6-Keto-PGF1αwas significantly decreased com-
pared with untreated mice (P < 0.01).
Discussion
Our findings suggest that liqi has a significant anti-tumor
effect against Sarcoma 180 tumor and Lewis lung carci-
noma, which is likely because of its immune-modulating
effects. Liqi enhanced NK cell activity, increased the Th/Ts
ratio, stimulated the production and activity of IL-2 in
splenocytes, and increased TNF-α activity in serum. More-
over, liqi inhibited the Lewis lung carcinoma metastasis,
which might be related to its inhibition of platelet aggre-
gation and normalization of the balance between TXA2
and PGI2. Furthermore, liqi inhibited the human gastric
carcinoma growth in xenografted mice. We demonstrated
that liqi has an anti-tumor effect and this effect may be
related to immune regulation and anticoagulation.
Previous reports have shown that the constituents of liqi
had an anti-tumor effect in vitro. We have shown that
treatment with liqi inhibited tumor growth in vivo. We
found that liqi arrested the proliferation of the human
gastric carcinoma cell line SGC-7901 from xenografted
mice in the G0/G1 phase and reduced the proportion of
cells in the S and G2/M phases (mitotic/dividing phases).
Although the mechanisms underlying liqi's anti-tumor
effect may be complex, our findings demonstrated that
this effect was most likely related to immune regulation.
Host immunity is implicated in the development and pro-
gression of malignant disease. Mice with tumors show a
change in T lymphocyte subpopulations and NK cell activ-
ity. T cells can affect tumor cells directly or can act indi-
rectly by producing cytokines that amplify cytotoxic T
lymphocyte responses or activate NK cells and macro-
phages. Experimental studies have outlined the critical
Effect of Liqi on T lymphocyte subpopulations in tumor-bear- ing mice Figure 2
Effect of Liqi on T lymphocyte subpopulations in 
tumor-bearing mice. Sarcoma 180 tumor cells were sub-
cutaneously implanted (2 × 106 cells suspended in 50 μl of 
PBS) in the right axillary region of syngeneic BALB/c mice. 
After 24 h, Liqi (50 g/kg) was administrated daily by gavage 
for 12 days. Peripheral blood lymphocyte subsets were meas-
ured by flow cytometry. Results are expressed as the mean ± 
S.D. of 12 mice. *P < 0.05, compared with untreated control 
of tumor-transplanted animals (model group). The normal 
group indicates healthy animals without tumor xenograft for 
comparison.
Effect of Liqi on IL-2 activity in tumor-bearing mice Figure 3
Effect of Liqi on IL-2 activity in tumor-bearing mice. 
Sarcoma 180 tumor cells were subcutaneously implanted (2 
× 106 cells suspended in 50 μl of PBS) in the right axillary 
region of syngeneic BALB/c mice. After 24 h, liqi (50 g/kg) 
was administrated daily by gavage for 12 days. IL-2 produc-
tion and activity in splenocyte supernatants were tested using 
an IL-2-dependent CTLL-2 cell proliferation assay. Results 
are expressed as the mean ± S.D. of 12 mice. **P < 0.01, 
compared with untreated control of tumor-transplanted ani-
mals (model group). The normal group indicates healthy ani-
mals without tumor xenograft for comparison.BMC Complementary and Alternative Medicine 2009, 9:20 http://www.biomedcentral.com/1472-6882/9/20
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role of CD4+ and CD8+ T cells and NK cells in mediating
anti-tumor immunity [17-20]. The present study confirms
the decrease in the ratio of CD4+/CD8+ with increasing
tumor burden, which appeared to result mainly from a
decrease in CD4+ T cells and an increase in CD8+ T cells.
However, the results also showed that the number of
CD4+ T cells and the CD4+/CD8+ ratio increased signifi-
cantly after administration of liqi, while the number of
CD8+ cells decreased. This finding indicates that liqi can
regulate the disordering of T lymphocyte subsets and
improve the immune response.
We also found that administering liqi increased the activ-
ity of NK cells in tumor-bearing mice. NK cells are the
major mediators of the innate anti-tumor immune
responses; they eradicate tumors by recognizing stress-
inducible ligands on tumors and execute tumor cells with
perforin and granzyme in vivo [21]. NK cells eradicate
solid tumors by apoptosis [21]. Liqi augments the cyto-
toxic potential of NK cells in vivo. Our data show that liqi
reversed tumor-mediated suppression of NK cell cytotox-
icity.
We found that the anti-tumor activity of liqi might also be
related to its regulatory effects on IL-2 and TNF-α, both of
which play important roles in cancer therapy [22,23]. IL-
2 has an anti-tumor effect because of its immune-regulat-
ing function [24], TNF-α had an anti-tumor activity
against sarcoma 180. In addition to direct cytotoxicity
against tumor cells, TNF induced a host-mediated factor
which contributed to the anti-tumor effects [25]. Rychly J
et al. [26] also demonstrated that TNF-α induced strong
necrosis in sarcoma 180 in vivo and showed total regres-
sion. The infiltration of inflammatory cells was observed
in the sarcoma 180 tumor. Their result suggested that cell
infiltration may be of importance for tumor regression. A
synergistic anti-tumor effect has been observed when
TNF-α is combined with IL-2 [27]. We demonstrate that
liqi can stimulate the production and activity of IL-2 and
TNF-α in mouse Sarcoma 180 tumor-bearing mice.
Furthermore, we demonstrated that liqi inhibited metas-
tasis of Lewis lung carcinomas. Metastasis is the major
cause of death from cancer. Tumor-induced platelet aggre-
gation is believed to protect tumor cells from immunolog-
ical assault in circulation [28]; platelets protect tumors
from TNF-α-mediated cytotoxicity [29]. Platelets also
facilitate the adhesion of tumor cells to the vascular
endothelium and release a number of growth factors that
Effect of Liqi on NK cell cytotoxicity in tumor-bearing mice Figure 4
Effect of Liqi on NK cell cytotoxicity in tumor-bear-
ing mice. Sarcoma 180 tumor cells were subcutaneously 
implanted (2 × 106cells suspended in 50 μl of PBS) in the 
right axillary region of syngeneic BALB/c mice. After 24 h, liqi 
(50 g/kg) was administrated daily by gavage for 12 days. NK 
cell cytotoxicity was tested using YAC-1 cells as target cells. 
LDH in culture supernatants was determined using the LDH 
Cytotox assay kit according to the manufacturer's instruc-
tions. Results are expressed as the mean ± S.D. of 12 mice. 
*P < 0.05, compared with untreated control of tumor-trans-
planted animals (model group). The normal group indicates 
healthy animals without tumor xenograft for comparison.
Effect of Liqi on TNF-α activity in tumor-bearing mice Figure 5
Effect of Liqi on TNF-α activity in tumor-bearing 
mice. Sarcoma 180 tumor cells were subcutaneously 
implanted (2 × 106 cells suspended in 50 μl of PBS) in the 
right axillary region of syngeneic BALB/c mice. After 24 h, 
Liqi (50 g/kg) was administrated daily by gavage for 12 days. 
Then tumor-bearing BALB/c mice received 20 μg/0.2 ml of 
LPS intravenously. After 1.5 h, blood samples were collected 
from the mice's orbital plexuses. TNF activity was deter-
mined by a cytotoxicity assay on L929 cells. The percent 
cytotoxicities were plotted against the logarithm of sample 
quantity. One unit of TNF activity was defined as the sample 
quantity required to achieve 50% cytotoxicity in the reaction. 
Results are expressed as the mean ± S.D. of 12 mice. ** P < 
0.01, compared with untreated control of tumor-trans-
planted animals (model group).BMC Complementary and Alternative Medicine 2009, 9:20 http://www.biomedcentral.com/1472-6882/9/20
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promote tumor growth [30]. Recently, it has been
reported that platelets contribute to tumor-induced ang-
iogenesis by releasing angiogenic growth factors, such as
vascular endothelial growth factor [31]. Our results dem-
onstrated that platelet aggregation was increased in C57BL
mice with Lewis lung carcinomas, and liqi inhibited plate-
let aggregation in these mice.
PGI2, a potent vasodilator and inhibitor of platelet aggre-
gation, is an important antithrombotic mediator in vivo
[32]. It also inhibits carcinogenesis [33]. Conversely, TXA2
stimulates platelet aggregation and amplifies the response
to other platelet agonists [34]. We demonstrated that the
level of PGI2 in serum was decreased and the level of TXA2
was increased, which resulted in an increased T/P ratio in
C57BL mice with Lewis lung carcinomas. However, Liqi
treatment inhibited the increase in the T/P ratio.
Conclusion
In summary, we demonstrated for the first time that liqi
has a significant inhibitory effect on tumor growth in vivo.
This inhibition may be related to the immunoregulatory
effects of liqi, such as stimulating IL-2 and TNF-α produc-
tion and activity and increasing the ratio of CD4+ to
CD8+ T lymphocytes and the activity of NK cells. These
data lead us to propose that the anticancer function of liqi
is underpinned by the improvement of immune function.
Furthermore, liqi has a significant inhibitory effect on
tumor metastasis, which is most likely related to its anti-
coagulation effects. These findings provide an experimen-
tal basis for the use of liqi for tumor therapy. The findings
Table 4: Effect of Liqi on TXA2 and PGI2 in tumor-bearing mice.
Groups Doses (g/kg) TXB2 (pg/ml) 6-Keto-PGF1α (pg/ml) T/P
Normal 0 1011.64 ± 102.57** 404.12 ± 51.33** 2.72 ± 0.78**
Model 0 1583.5 ± 102.45 178 ± 31.12 8.76 ± 1.67
Liqi 50 1185.43 ± 148.45** 323.15 ± 104.25** 4.81 ± 1.22**
Each group consists of 12 mice. Results are presented as mean ± S.D. **P < 0.01, compared with model group.
Effect of Liqi on platelet aggregation in tumor-bearing mice Figure 7
Effect of Liqi on platelet aggregation in tumor-bear-
ing mice. Lewis lung carcinoma cells were subcutaneously 
implanted (2 × 106 LLC tumor cells suspended in 50 μl of 
PBS) in the right axillary region of syngeneic C57BL/6 mice. 
After 24 h, Liqi (50 g/kg) was administrated daily by gavage 
for 21 days. Platelet aggregation was monitored by measuring 
electric impedance using a whole-blood aggregometer. 
Results are expressed as the mean ± S.D. of 12 mice. *P < 
0.05, compared with untreated control of tumor-trans-
planted animals (model group). The normal group indicates 
healthy animals without tumor xenograft for comparison.
Effect of Liqi on metastasis of tumor cells to the lungs Figure 6
Effect of Liqi on metastasis of tumor cells to the 
lungs. Lewis lung carcinoma cells were subcutaneously 
implanted (2 × 106 LLC tumor cells suspended in 50 μl of 
PBS) in the right axillary region of syngeneic C57BL/6 mice. 
After 24 h, Liqi (50 g/kg) was administrated daily by gavage 
for 21 days. Lungs were removed and fixed in 4% formalin. 
Tumor colonies were counted under microscope (×200). 
Results are expressed as the mean ± S.D. of 12 mice. * P < 
0.05, compared with model group. The normal group indi-
cates healthy animals without tumor xenograft for compari-
son.BMC Complementary and Alternative Medicine 2009, 9:20 http://www.biomedcentral.com/1472-6882/9/20
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of our study may shed light on the pharmacologic basis
for the clinical application of traditional Chinese medi-
cine in treating cancer.
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